Phase 4
Completed N=61
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Autistic Disorder
Source: ClinicalTrials.gov NCT01333072 ↗
Enrolled (actual)
61
Serious AEs
0.0%
Results posted
Sep 2018
Primary outcomePrimary: Changes in the Irritability Subscale of the Larger ABC (Abberent Behavior Checklist) That Occur From Baseline to 10 Weeks — 12.7; 14.1 units on a scale
◆ Published Evidence
Established
54citations · ~8 / year
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
Summary
The Biomarkers in autism of aripiprazole and risperidone treatment (BAART) project will provide evidence-based guidance in the selection and monitoring of drug treatment of autism. BAART involves 3 academic centers across South Carolina. Although the FDA has approved use of the antipsychotic drug risperidone for irritability associated with autistic disorder, a moderate response rate in pivotal clinical trials and concerns over tolerability and weight gain can force clinicians to select alternative drug treatments for which evidence-based support is sparse.
Linked Publications (2)
-
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
-
Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Changes in the Irritability Subscale of the Larger ABC (Abberent Behavior Checklist) That Occur From Baseline to 10 Weeks |
12.7; 14.1 | — |
Eligibility Criteria
Inclusion Criteria
- Aged 6 to 17 years and weight of at least 15 kg
- Meet DSM-IV criteria for of AD, established by chart review, clinical judgment and the Autism Diagnostic Interview- Revised (ADI-R) criteria
- Clinical Global Impressions Severity (CGI-S) score of >4 (moderately ill)
- ABC Irritability subscale score of >18
- Mental age of at least 18 months
- If female and sexually active, must agree to an acceptable method of birth control during the trial
- Medication free or adequate washout period (2-4 weeks prior to enrollment) of psychoactive drugs (anticonvulsants permitted for seizure management if dosage is stable for 4 weeks)
- Parent/guardian able to read and provide informed consent.
Exclusion Criteria
- Psychiatric disorder that is effectively managed by psychoactive medication (e.g. ADHD, MDD)
- Prior diagnosis or evidence of genetic or other disorder that may interfere with assessments (e.g. Fragile X syndrome, Fetal alcohol syndrome, history of very low birth weight) assessed by personal and family history, dysmorphology, and clinical judgment.
- Prior use of risperidone or aripiprazole for more than 2 weeks
- Seizure during the past 6 months
- History or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments during the trial including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, hematologic or immunologic disease as determined by the clinical judgment of the investigator
- Current suicidal or homicidal risk
- Positive urine pregnancy test at baseline
- Dependent on other substances, with the exception of nicotine or caffeine
Data sourced from ClinicalTrials.gov (NCT01333072) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.